Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Baylor College of Medicine Establish Metabolomics Mass Spec Center

NEW YORK (GenomeWeb) – Agilent and Baylor College of Medicine said yesterday that they have opened an Agilent Mass Spectrometry Center of Excellence at BCM'sAlkekCenterfor Molecular Discovery.

Agilent is providing the center with two mass spec systems for metabolomics work: a 6495 triple quadrupole LC/MS system and a 6550 iFunnel QTOF LC/MS system with a switchable GC APCI interface.

The systems will also include Agilent's Mass Hunter software for qualitative and quantitative work and its Mass Profiler Professional with Pathway Architect for bioinformatics and multiomic analyses.

"The growing significance of metabolomics, not only in life science research but in many application spaces, has resulted in the need for more analytical capabilities,” Arun Sreekumar, co-director of the Alkek Center, said in a statement. "Baylor and Agilent have identified several areas of mutual interest — metabolomics, lipidomics, clinical research, disease research — where we believe we can make real progress together."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.